Oculis Holding AG
Privosegtor
optic neuritis
Countdown
83days
FDA decision · Sep 27, 2026
What's at stake
The FDA's approval decision on Privosegtor for optic neuritis is due Sep 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 11h ago
“In May 2026, we received written agreement from the FDA under a Special Protocol Assessment (SPA) regarding PIONEER-1 to confirm that the design and planned analysis of the PIONEER-1 study are adequate to address the objectives necessary to”